Relation of serum uric acid level with cognitive functions and number of plaques in patients with relapsing-remitting multiple sclerosis;Relapsing-Remitting Multipl Skleroz Hastalarında Serum Ürik Asit Düzeyinin Kognitif Fonksiyonlar ve Plak Sayısı ile İlişkisi

Noropsikiyatri Arsivi

Volumn 47, Issue 4, 2010, Pages 333-337

  Yoldaş, Tahir Kurtuluş ^a   Keklikoǧlu, Hava Dönmez ^a   Zengin, Özkan ^a   Solak, Elif Banu ^a   Keskin, Selda ^a  

^a Di kapi Yildirim Beyazit E itim ve Ara tirma Hastanesi   (Turkey)

Author keywords

Cognitive function; Multiple sclerosis; Uric acid

Indexed keywords

URIC ACID;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; BRAIN DAMAGE; CLINICAL ARTICLE; CLINICAL EVALUATION; COGNITIVE DEFECT; DISEASE ASSOCIATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LABORATORY TEST; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; SEX DIFFERENCE; URIC ACID BLOOD LEVEL;

EID: 79251581636     PISSN: 13000667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Rogers JM, Panegyres PK. Cognitive impairment in multiple sclerosis:Evidence-based analysis and recommendation. Journal of Clinical Neuroscience 2007; 14:919-27. [Abstract] / [Full Text] / [PDF]
2. Ranjeva JP, Audoin B, Au duong MV et al. Structural and functional surrogates of cognitive impairment at the very early stage of multiple sclerosis. J Neurol Sci 2006; 245:161-7. [Abstract]
3. Euser SM, Hofman A, Westendorp RGJ, Breteler MMB. Serum uric acid and cognitive function and dementia. Brain 2009; 132:377-82. [Abstract] / [Full Text] / [PDF]
4. Irizarry MC, Raman R, Schwarzschild MA et al. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis. 2009; 6:23-8. [Abstract] / [Full Text] / [PDF]
5. Rentzos M, Nikolaou C, Anagnosrouli M et al. Serum uric acid and multiple sclerosis. Clinical Neurology and Neurosurgery 2006;108:527-31. [Abstract] / [Full Text] / [PDF]
6. Drulovic J, Dujmovic I, Stojsavljevic N and et al. Uric Cid level in sera from patients with multiple sclerosis. J Neurol 2001; 248:121-6. [Abstract] / [Full Text]
7. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227-31. [Abstract]
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983:1444-52. [Abstract]
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 1960; 23:56-62.
10. Akdemir A, Türkçapar MG, Örsel SD et al. Reability and validity of Turkish version of the Hamilton Depression Rating Scale. Compr Psychiatry 2001; 42:161-5. [Abstract] / [PDF]
11. Rosen G, Mohs RC, David KL. A new Rating Scale for Alzheimer's Disease. Am J Psychiatry 1984; 141:1356-64. [Abstract] / [PDF]
12. Akca Kalem S, Oktem O, Hanagasi HA et al. Determination of the descriptive statistics for Alzheimer's Disease Assesment Scale-Cognitive Subscore (ADAS-cog) in a normal adult Turkish sample. Archives of Neuropsychiatry 2003; 40:13-25. [Full Text] / [PDF]
13. Hooper DC, Spitsin S, Kean RB et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalo-myelitis and multiple sclerosis. Proc Natl Acad Sci USA 1998; 95:675-80. [Abstract] / [Full Text] /[PDF]
14. Scott GS, Spitsin SV, Kean RB et al. Therapeutic intevention in experimental allergic encephalomyelitis by administration of uric acid precursors. PNAS 2002; 99:16303-8. [Abstract] / [Full Text] / [PDF]
15. Euser SM, Hofman A, Westendorp RG, Breteler MM. Serum uric acid and cognitive function and dementia. Brain 2009; 132:377-82. [Abstract] / [Full Text] /[PDF]
16. Rao SM, Leo GJ, Bernardin L et al. Cognitive dysfunction in multiple sclerosis: Frequency, patterns and predictions. Neurology 1991; 41:685-91. [Abstract]
17. Achiron A, Barak Y. Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry. 2003; 74:443-6. [Full Text] / [PDF]
18. Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001; 58:1602-6. [Abstract] / [Full Text] / [PDF]
19. Lynch SG, Parmanter BA, Denney DR. The association between cognitive impairment and physical disability in multiple sclerosis. Mult Scler 2005; 11:469-76. [Abstract] / [Full Text] / [PDF]
20. Scwid SR, Goodman AD, Weinstein A et al. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J Neurol Sci 2007; 255:57-63. [Abstract] / [Full Text] / [PDF]
21. Achiron A, M Polliack, S Rao, Y et al. Cognitive patterns and progression in multiple sclerosis: construction and validation of percentile curves. J Neurol Neurosurg Psychiatry. 2005; 76:744-9. [Full Text] /[PDF]
22. Beatty WW, Goodkin DE. Screening for cognitive impairment in multiple sclerosis. An evaluation of the Mini-Mental State Examination. Arch Neurol. 1990; 47:297-301. [Abstract] / [PDF]
23. Swirsky-Sacchetti T, Field HL, Mitchell DR et al. The sensitivity of the Mini-Mental State Exam in the white matter dementia of multiple sclerosis. J Clin Psychol. 1992; 48:779-86. [Abstract]
24. Krupp LB. Fatigue in multiple sclerosis: definition pathophysiology and treatment. CNS Drugs 2003; 17:225-34. [Abstract]
25. Dalton EJ, Heinrichs RW. Depression in multiple sclerosis: a quantitative review of the evidence. Neuropsycology. 2005; 19:152-8. [Abstract] / [Full Text] / [PDF]
26. Bobholz JA, Rao SM. Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 2003; 16:283-8. [Abstract]
27. Rogers JM, Panegyres PK. Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendation. J Clin Neurosci 2007; 14:919-27. [Abstract] / [Full Text] / [PDF]
28. Amorini AM, Petzold A, Tavazzi B et al. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem. 2009; 42:1001-6. [Abstract] / [Full Text] / [PDF]
29. Rentzos M, Nikolaou C, Anagnostouli M et al. Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg. 2006; 108:527-31.
30. Sotgiu S, Pugliatti M, Sanna A et al. Serum uric acid and multiple sclerosis. Neurol Sci 2002; 23:183-8. [PDF]
31. Knapp CM, Constantinescu CS, Tan JH et al. Serum uric acid levels in optic neuritis. Mult Scler 2004; 10:278-80. [Abstract] / [PDF]
32. Koch M, De Keyser J. Uric acid in multiple sclerosis. Neurol Res. 2006; 28:316-9. [Abstract]
33. Pati F. Cognitive impairment in multiple sclerosis. Multiple Sclerosis 2009; 15:2-8. [Abstract] / [PDF]